Zhejiang Haisen Pharmaceutical Co., Ltd. (SHE:001367)

SHE:001367 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Cash & Equivalents	517.65	909.49	1,034	943.75	247.19	205.26
Trading Asset Securities	620.2	151.7	-	-	-	0.74
Cash & Short-Term Investments	1,138	1,061	1,034	943.75	247.19	206
Cash Growth	12.78%	2.58%	9.61%	281.79%	19.99%	47.24%
Accounts Receivable	78.32	103.38	89.2	57.73	47.3	44.61
Other Receivables	0.26	5.35	15.17	14.94	0.04	2.81
Receivables	78.58	108.73	104.38	72.67	47.34	47.42
Inventory	116.56	108.47	115.48	159.31	142.65	104.94
Other Current Assets	4.38	2.45	3.29	2.25	9.01	2.39
Total Current Assets	1,337	1,281	1,258	1,178	446.19	360.75
Property, Plant & Equipment	258.34	224.97	201.51	134.9	85.64	85.89
Other Intangible Assets	115.91	117.82	20.14	19.78	19.74	20.26
Long-Term Deferred Tax Assets	-	-	-	-	1.79	1.37
Long-Term Deferred Charges	0.26	0.21	0.27	0.26	1.8	3.27
Other Long-Term Assets	12.97	6.42	6.45	8.04	10.45	5.76
Total Assets	1,725	1,630	1,486	1,341	565.6	477.31

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Accounts Payable	43.61	44.88	52.16	46.55	34.94	56.28
Accrued Expenses	16.4	23.72	18.21	15.65	14.73	14.97
Current Portion of Leases	-	1.33	1.14	0.07	0.78	0.75
Current Income Taxes Payable	16.96	13.83	9.58	6.05	21.61	11.33
Current Unearned Revenue	4.53	3.85	7.92	4.16	7.08	9.49
Other Current Liabilities	34.82	28.69	33.04	6.3	4.26	10.04
Total Current Liabilities	117.54	116.3	122.04	78.77	83.4	102.86
Long-Term Leases	6.2	6.1	6.98	0.1	-	0.78
Long-Term Unearned Revenue	9.39	4.79	5.39	5.85	6.22	5.59
Long-Term Deferred Tax Liabilities	5.57	9.29	7.43	6.89	6.7	6.78
Other Long-Term Liabilities	-	-	-	-	0.24	-
Total Liabilities	138.69	136.48	141.84	91.62	96.57	116.02

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Common Stock	152.35	152.35	102.65	68	51	51
Additional Paid-In Capital	743.25	734.83	759.97	763.02	104.3	104.3
Retained Earnings	707.54	624.05	505.63	417.07	312.4	204.88
Treasury Stock	-18.86	-18.86	-25.46	-	-	-
Comprehensive Income & Other	1.85	1.38	1.37	1.25	1.33	1.11
Shareholders' Equity	1,586	1,494	1,344	1,249	469.03	361.29
Total Liabilities & Equity	1,725	1,630	1,486	1,341	565.6	477.31

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Total Debt	7.42	7.43	8.12	0.17	0.78	1.53
Net Cash (Debt)	1,130	1,054	1,026	943.59	246.41	204.47
Net Cash Growth	13.00%	2.67%	8.77%	282.94%	20.51%	46.15%
Net Cash Per Share	7.36	6.90	6.87	6.88	2.21	1.83
Filing Date Shares Outstanding	154.16	148.75	148.95	148.95	111.71	111.71
Total Common Shares Outstanding	154.16	148.75	148.95	148.95	111.71	111.71
Working Capital	1,220	1,165	1,136	1,099	362.78	257.89
Book Value Per Share	10.29	10.04	9.02	8.39	4.20	3.23
Tangible Book Value	1,470	1,376	1,324	1,230	449.29	341.03
Tangible Book Value Per Share	9.54	9.25	8.89	8.25	4.02	3.05
Buildings	-	104.42	59.66	55.1	52.99	53.03
Machinery	-	199.4	149.06	123.92	107.08	106.47
Construction In Progress	-	21.36	73.59	48.05	8.41	0.93

Data Source: S&P Global Market Intelligence Last updated: Oct 22, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 27, 2026

Data Sources Report a data error